EL7.AI
StocksMediumUpdated×3•Originally published 29 October 2026•Updated 30 October 2026•
3 min read

Insmed Revenue Jumps 268% to $524.4 Million in Third Quarter

Key Facts

1Insmed revenue reached $524.4 million in the third quarter of 2026, up 268% from the year-earlier period.
2The company raised its 2026 Arikayce revenue forecast to $460–470 million, from a previous low end of $450 million.
3Insmed's net loss was $100.3 million, or $0.46 a share, in the third quarter of 2026.
4Arikayce revenue was $124.4 million, up 9% year over year in the third quarter.
5Cash, cash equivalents and marketable securities totaled about $1.1 billion as of September 30, 2026.

Insmed said on October 29 that revenue reached $524.4 million in the third quarter ended September 30, 2026, up 268% from $142.3 million in the year-earlier period. The company said the quarter reflected commercial momentum, regulatory achievements and progress across its pipeline. Management raised the low end of its full-year revenue forecasts for Brensocatib and Arikayce, while leaving the high end of each range unchanged. Chief Executive Will Lewis said the U.S. launch of Brensocatib "continues to exceed expectations" and Arikayce "continues to grow in its ninth year on the market." The company's shares closed at $111.59 on October 29, after closing at $96.98 the previous day.

The revenue jump came alongside a narrower net loss, as Insmed posted a loss of $100.3 million, or $0.46 a share, in the third quarter of 2026. The company reported a net loss of $370.0 million, or $1.75 a share, in the third quarter of 2025. The improvement puts the current-quarter loss in the context of the sales growth the company reported, but does not change the fact that it remained loss-making. Management also linked the period's growth to commercial momentum, regulatory progress and advances across its diverse pipeline. The company did not provide an available comparison between actual per-share loss and analysts' estimates.

Brensocatib was a key focus of the forecast update, with management saying strong U.S. market growth drove its revenue growth and that its launch there exceeded expectations. In August 2026, Japan's Ministry of Health, Labour and Welfare approved the drug to treat non-cystic fibrosis bronchiectasis in adults and children aged 12 and older. The company said the commercial launch in Japan took place in October, without specifying a date. The Japanese launch adds a new market to the drug's commercial expansion, following the regulatory approval announced in August. In its long-term outlook, Insmed said it expects peak revenue for Brensocatib to exceed $7 billion.

Insmed raised its fiscal 2026 revenue forecast for Arikayce to a range of $460 million to $470 million, from a previous range of $450 million to $470 million. The drug generated revenue of $124.4 million in the third quarter, up 9% year over year, driven mainly by growth in international markets. Lewis said Arikayce continues to grow in its ninth year on the market, placing its current performance alongside Brensocatib's expansion in the company's account of its results. Over the long term, Insmed expects peak revenue for Arikayce to exceed $1 billion. The U.S. Food and Drug Administration also granted priority review to the drug's supplemental application and set January 28, 2027, as its target decision date.

The company reported financial resources of about $1.1 billion in cash, cash equivalents and marketable securities as of September 30, 2026. That balance comes as Insmed advances its clinical programs alongside marketing its two drugs, with long-term peak revenue expectations of more than $7 billion for Brensocatib, $6 billion for TPIP and $1 billion for Arikayce. Near-term milestones include submitting data from the Phase 3 ENCORE study to Japan's Pharmaceuticals and Medical Devices Agency during the fourth quarter of 2026. The company aims to use the data submission to support a potential expansion of Arikayce's label in Japan. In the U.S., the FDA's target decision date of January 28, 2027, for Arikayce's supplemental application remains the next specified regulatory milestone.

Open on chart